Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Purpose: Patient-derived xenograft (PDX) models accurately recapitulate the tumor of origin in terms of histopathology, genomic landscape, and therapeutic response, but some limitations due to costs associated with their maintenance and restricted amenability for large-scale screenings still exist. To overcome these issues, we established a platform of 2D cell lines (xeno-cell lines, XL), derived from PDXs of colorectal cancer with matched patient germline gDNA available. Experimental Design: Whole-exome and transcriptome sequencing analyses were performed. Biomarkers of response and resistance to anti-HER therapy were annotated. Dependency on the WRN helicase gene was assessed in MSS, MSI-H, and MSI-like XLs using a reverse genetics functional approach. Results: XLs recapitulated the entire spectrum of colorectal cancer transcriptional subtypes. Exome and RNA-seq analyses delineated several molecular biomarkers of response and resistance to EGFR and HER2 blockade. Genotype-driven responses observed in vitro in XLs were confirmed in vivo in the matched PDXs. MSI-H models were dependent upon WRN gene expression, while loss of WRN did not affect MSS XLs growth. Interestingly, one MSS XL with transcriptional MSI-like traits was sensitive to WRN depletion. Conclusions: The XL platform represents a preclinical tool for functional gene validation and proof-of-concept studies to identify novel druggable vulnerabilities in colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“Confirming previous reports (27, 46), both CRIS-C and CMS2 transcriptional classes are enriched for cetuximab responsive models (Supplementary Table S4).”
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051
Self-citationNext-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184 · cited 1×
“The putative biological significance in cancer of these private mutations was assessed on the basis of Cancer Gene Census and data reported from colorectal cancer analysis (32, 33).”
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · cited 1×
“The putative biological significance in cancer of these private mutations identified only in XLs (n=4174) or PDXs (n=1997) was assessed on Cancer Gene Census and data reported from CRC analysis (35,36).”
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“Indeed, the Cancer Cell Line Encyclopedia, the Genomics of Drug Sensitivity in Cancer (GDSC) Sanger Institute project, the National Cancer Institute-60 (NCI-60) cancer cell line screen, and the Cancer Therapeutic Response Portal (CTRP) constitute paradigmatic examples of how coupling cell lines to systematic compound…”
Self-citationDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Lentiviral control vectors (pRLL empty and FG12 empty), pRLL-KRAS WT, pRLL-KRAS G13D, and FG12-BRAF V600E vectors were previously exploited (29, 30).”
Self-citationPatient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationPrioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338
Self-citation
Research works printed but not linked: 40
- Kelloff, 2012, Cancer biomarkers: selecting the right drug for the right patient, Nat Rev Drug Discov, 11, 201, 10.1038/nrd3651 · DOI · Paper page
- The Cancer Genome Atlas Network, 2012, Comprehensive molecular characterization of human colon and rectal cancer, Nature, 487, 330, 10.1038/nature11252 · DOI · Paper page
- Bruna, 2016, A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds, Cell, 167, 260, 10.1016/j.cell.2016.08.041 · DOI · Paper page
- Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 · DOI · Paper page
- Gillet, 2013, The clinical relevance of cancer cell lines, J Natl Cancer Inst, 105, 452, 10.1093/jnci/djt007 · DOI · Paper page
- Byrne, 2017, Interrogating open issues in cancer precision medicine with patient-derived xenografts, Nat Rev Cancer, 17, 254, 10.1038/nrc.2016.140 · DOI · Paper page
- Julien, 2012, Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer, Clin Cancer Res, 18, 5314, 10.1158/1078-0432.CCR-12-0372 · DOI · Paper page
- Galimi, 2011, Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations, Clin Cancer Res, 17, 3146, 10.1158/1078-0432.CCR-10-3377 · DOI · Paper page
- Ben-David, 2017, Patient-derived xenografts undergo mouse-specific tumor evolution, Nat Genet, 49, 1567, 10.1038/ng.3967 · DOI · Paper page
- Damhofer, 2015, Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract, J Transl Med, 13, 115, 10.1186/s12967-015-0469-1 · DOI
- Knudsen, 2018, Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility, Gut, 67, 508, 10.1136/gutjnl-2016-313133 · DOI · Paper page
- Luraghi, 2018, A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy, Clin Cancer Res, 24, 807, 10.1158/1078-0432.CCR-17-2151 · DOI
- Maletzki, 2012, Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas, PLoS One, 7, e52485, 10.1371/journal.pone.0052485 · DOI
- Niu, 2014, MSIsensor: microsatellite instability detection using paired tumor-normal sequence data, Bioinformatics, 30, 1015, 10.1093/bioinformatics/btt755 · DOI · Paper page
- Corti, 2019, A genomic analysis workflow for colorectal cancer precision oncology, Clin Colorectal Cancer, 18, 91, 10.1016/j.clcc.2019.02.008 · DOI · Paper page
- Li, 2011, RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome, BMC Bioinformatics, 12, 323, 10.1186/1471-2105-12-323 · DOI · Paper page
- Isella, 2017, Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer, Nat Commun, 8, 15107, 10.1038/ncomms15107 · DOI · Paper page
- Di Nicolantonio, 2008, Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses, Proc Natl Acad Sci U S A, 105, 20864, 10.1073/pnas.0808757105 · DOI · Paper page
- Alexandrov, 2013, Signatures of mutational processes in human cancer, Nature, 500, 415, 10.1038/nature12477 · DOI · Paper page
- Giannakis, 2014, RNF43 is frequently mutated in colorectal and endometrial cancers, Nat Genet, 46, 1264, 10.1038/ng.3127 · DOI · Paper page
- Markowitz, 1995, Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability, Science, 268, 1336, 10.1126/science.7761852 · DOI · Paper page
- Rodríguez-Escudero, 2011, A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes, Hum Mol Genet, 20, 4132, 10.1093/hmg/ddr337 · DOI · Paper page
- Han, 2000, Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay, Cancer Res, 60, 3147
- Zanella, 2015, IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies, Sci Transl Med, 7, 272ra12, 10.1126/scitranslmed.3010445 · DOI · Paper page
- Arena, 2015, Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer, Clin Cancer Res, 21, 2157, 10.1158/1078-0432.CCR-14-2821 · DOI · Paper page
- Siravegna, 2015, Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, Nat Med, 21, 795, 10.1038/nm.3870 · DOI · Paper page
- Russo, 2016, Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer, Cancer Discov, 6, 147, 10.1158/2159-8290.CD-15-1283 · DOI · Paper page
- Russo, 2016, Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer, Cancer Discov, 6, 36, 10.1158/2159-8290.CD-15-0940 · DOI · Paper page
- Leto, 2015, Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas, Clin Cancer Res, 21, 5519, 10.1158/1078-0432.CCR-14-3066 · DOI · Paper page
- Siravegna, 2018, Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer, Cancer Cell, 34, 148, 10.1016/j.ccell.2018.06.004 · DOI · Paper page
- Kategaya, 2019, Werner syndrome helicase is required for the survival of cancer cells with microsatellite instability, iScience, 13, 488, 10.1016/j.isci.2019.02.006 · DOI · Paper page
- Lieb, 2019, Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells, eLife, 8, e43333, 10.7554/eLife.43333 · DOI · Paper page
- Tian, 2012, A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency, J Pathol, 228, 586, 10.1002/path.4092 · DOI · Paper page
- Jernström, 2017, Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response, Breast Cancer, 9, 185
- Chen, 2012, MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells, Mol Cancer Ther, 11, 660, 10.1158/1535-7163.MCT-11-0754 · DOI · Paper page
- Amirouchene-Angelozzi, Tumor evolution as a therapeutic target, Cancer Discov
- Dangles-Marie, 2007, Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features, Cancer Res, 67, 398, 10.1158/0008-5472.CAN-06-0594 · DOI · Paper page
- Lee, 2018, Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy, Nat Genet, 50, 1399, 10.1038/s41588-018-0209-6 · DOI · Paper page
- Pauli, 2017, Personalized in vitro and in vivo cancer models to guide precision medicine, Cancer Discov, 7, 462, 10.1158/2159-8290.CD-16-1154 · DOI · Paper page
- Rospo, 2019, Evolving neoantigen profiles in colorectal cancers with DNA repair defects, Genome Med, 11, 42, 10.1186/s13073-019-0654-6 · DOI
Cited by
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504
“Taking advantage of our molecularly and therapeutically annotated CRC patient-derived bio-bank (25-27), in a cohort of more than one hundred patient-derived organoids (PDO), we selected three different KRAS G12C mutant PDOs and one KRAS G12D mutant PDO (as negative control) and tested the effects of single agents AMG5…”
MethodSelf-citationPatient-derived xenograft models in cancer therapy: technologies and applications
Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 494
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2409 · Cited by 115
“Cell lines and cell authentication All colorectal cancer cell lines are part of datasets we previously characterized (34, 35).”
BackgroundSelf-citationStrategies to tackle RAS-mutated metastatic colorectal cancer
Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D. A., Pani, A., Scaglione, F., Siena, S., & Sartore-Bianchi, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100156 · Cited by 86
Self-citationPatient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer
Rizzo, G., Bertotti, A., Leto, S. M., & Vetrano, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01970-2 · Cited by 51
Self-citation
Metadata
- Authors
- Lazzari, L., Corti, G., Picco, G., Isella, C., Montone, M., Arcella, P., Durinikova, E., Zanella, E. R., Novara, L., Barbosa, F., Cassingena, A., Cancelliere, C., Medico, E., Sartore-Bianchi, A., Siena, S., Garnett, M. J., Bertotti, A., Trusolino, L., Di Nicolantonio, F., Linnebacher, M., Bardelli, A., & Arena, S.
- Venue
- Clinical Cancer Research
- Published
- 2019-10-15
- Volume
- 25
- Issue
- 20
- Pages
- 6243-6259
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2965934400
- Cited by
- 74
- References
- 30
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- Molecular Pharmacology laboratory (CRC0080-XL)
- European Community's Seventh Framework Programme (602901 MErCuRIC, 635342-2 MoTriColor)
- European Research Council Consolidator (724748 - BEAT)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-3440
- The paper
- Lazzari, L., Corti, G., Picco, G., Isella, C., Montone, M., Arcella, P., Durinikova, E., Zanella, E. R., Novara, L., Barbosa, F., Cassingena, A., Cancelliere, C., Medico, E., Sartore-Bianchi, A., Siena, S., Garnett, M. J., Bertotti, A., Trusolino, L., Di Nicolantonio, F., . . . Arena, S. (2019). Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-3440
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.